[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA: a cancer journal for clinicians. 2018;68(1):7-30. doi:10.3322/caac.21442
[2] Anglesio MS, Carey MS, Köbel M, Mackay H, Huntsman DG. Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010. Gynecologic oncology. 2011;121(2):407-15. doi:10.1016/j.ygyno.2011.01.005
[3] Glasspool RM, McNeish IA. Clear cell carcinoma of ovary and uterus. Current oncology reports. 2013;15(6):566-72. doi:10.1007/s11912-013-0346-0
[4] del Carmen MG, Birrer M, Schorge JO. Clear cell carcinoma of the ovary: a review of the literature. Gynecologic oncology. 2012;126(3):481-90. doi:10.1016/j.ygyno.2012.04.021
[5] Bennett JA, Dong F, Young RH, Oliva E. Clear cell carcinoma of the ovary: evaluation of prognostic parameters based on a clinicopathological analysis of 100 cases. Histopathology. 2015;66(6):808-15. doi:10.1111/his.12514
[6] Clark TG, Stewart ME, Altman DG, Gabra H, Smyth JF. A prognostic model for ovarian cancer. Br J Cancer. 2001;85(7):944-52
[7] Ebina Y, Uchiyama M, Imafuku H, Suzuki K, Miyahara Y, Yamada H. Risk factors for deep venous thrombosis in women with ovarian cancer. Medicine. 2018;97(23):e11009. doi:10.1097/MD.0000000000011009
[8] Liu P, Wang Y, Tong L, Xu Y, Zhang W, Guo Z, et al. Elevated preoperative plasma D-dimer level is a useful predictor of chemoresistance and poor disease outcome for serous ovarian cancer patients. Cancer Chemother Pharmacol. 2015;76(6):1163-71. doi:10.1007/s00280-015-2900-y
[9] Wu J, Fu Z, Liu G, Xu P, Xu J, Jia X. Clinical significance of plasma D-dimer in ovarian cancer: A meta-analysis. Medicine. 2017;96(25):e7062. doi:10.1097/MD.0000000000007062
[10] Templeton AJ, McNamara MG, Seruga B, Vera-Badillo FE, Aneja P, Ocana A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Journal of the National Cancer Institute. 2014;106(6):dju124. doi:10.1093/jnci/dju124
[11] Ethier JL, Desautels DN, Templeton AJ, Oza A, Amir E, Lheureux S. Is the neutrophil-to-lymphocyte ratio prognostic of survival outcomes in gynecologic cancers? A systematic review and meta-analysis. Gynecol Oncol. 2017;145(3):584-94. doi:10.1016/j.ygyno.2017.02.026
[12] Kwon BS, Jeong DH, Byun JM, Lee TH, Choi KU, Song YJ, et al. Prognostic value of preoperative lymphocyte-monocyte ratio in patients with ovarian clear cell carcinoma. J Cancer. 2018;9(7):1127-34. doi:10.7150/jca.24057
[13] Yoshida K, Yoshikawa N, Shirakawa A, Niimi K, Suzuki S, Kajiyama H, et al. Prognostic value of neutrophil-to-lymphocyte ratio in early-stage ovarian clear-cell carcinoma. Journal of gynecologic oncology. 2019;30(6):e85. doi:10.3802/jgo.2019.30.e85
[14] Ocana A, Nieto-Jiménez C, Pandiella A, Templeton AJ. Neutrophils in cancer: prognostic role and therapeutic strategies. Molecular cancer. 2017;16(1):137. doi:10.1186/s12943-017-0707-7
[15] Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21(2):137-48
[16] Mei Z, Shi L, Wang B, Yang J, Xiao Z, Du P, et al. Prognostic role of pretreatment blood neutrophil-to-lymphocyte ratio in advanced cancer survivors: A systematic review and meta-analysis of 66 cohort studies. Cancer Treat Rev. 2017;58:1-13. doi:10.1016/j.ctrv.2017.05.005
[17] Zhao Z, Zhao X, Lu J, Xue J, Liu P, Mao H. Prognostic roles of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in ovarian cancer: a meta-analysis of retrospective studies. Archives of gynecology and obstetrics. 2018;297(4):849-57. doi:10.1007/s00404-018-4678-8
[18] Yang Z, Gu JH, Guo CS, Li XH, Yang WC. Preoperative neutrophil-to-lymphocyte ratio is a predictor of survival of epithelial ovarian cancer: a systematic review and meta-analysis of observational studies. Oncotarget. 2017;8(28):46414-24. doi:10.18632/oncotarget.16793
[19] Kim HS, Choi H-Y, Lee M, Suh DH, Kim K, No JH, et al. Systemic Inflammatory Response Markers and CA-125 Levels in Ovarian Clear Cell Carcinoma: A Two Center Cohort Study. Cancer research and treatment : official journal of Korean Cancer Association. 2016;48(1):250-8. doi:10.4143/crt.2014.324
[20] Zhang H, Lu J, Lu Y, Zhou J, Wang Z, Liu H, et al. Prognostic significance and predictors of the system inflammation score in ovarian clear cell carcinoma. PloS one. 2017;12(5):e0177520. doi:10.1371/journal.pone.0177520
[21] Sierzega M, Lenart M, Rutkowska M, Surman M, Mytar B, Matyja A, et al. Preoperative Neutrophil-Lymphocyte and Lymphocyte-Monocyte Ratios Reflect Immune Cell Population Rearrangement in Resectable Pancreatic Cancer. Ann Surg Oncol. 2017;24(3):808-15. doi:10.1245/s10434-016-5634-0
[22] Lin Y, Liu Z, Qiu Y, Zhang J, Wu H, Liang R, et al. Clinical significance of plasma D-dimer and fibrinogen in digestive cancer: A systematic review and meta-analysis. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2018;44(10):1494-503. doi:10.1016/j.ejso.2018.07.052
[23] Zhu LR, Li J, Chen P, Jiang Q, Tang XP. Clinical significance of plasma fibrinogen and D-dimer in predicting the chemotherapy efficacy and prognosis for small cell lung cancer patients. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2016;18(2):178-88. doi:10.1007/s12094-015-1350-7
[24] Li H, Zhao S, Jing Z, Li J, Shuanying Y, Zhang N. Combination of D-dimer and carcinoembryonic antigen levels as a predictive and prognostic biomarker in advanced colorectal cancer patients. J Cell Biochem. 2018. doi:10.1002/jcb.28087
[25] Yamada Y, Kawaguchi R, Iwai K, Niiro E, Morioka S, Tanase Y, et al. Preoperative plasma D-dimer level is a useful prognostic marker in ovarian cancer. Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology. 2020;40(1):102-6. doi:10.1080/01443615.2019.1606176
[26] Uno K, Homma S, Satoh T, Nakanishi K, Abe D, Matsumoto K, et al. Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer. Br J Cancer. 2007;96(2):290-5
[27] Miura K, Hamanaka K, Koizumi T, Kitaguchi Y, Terada Y, Nakamura D, et al. Clinical significance of preoperative serum albumin level for prognosis in surgically resected patients with non-small cell lung cancer: Comparative study of normal lung, emphysema, and pulmonary fibrosis. Lung Cancer. 2017;111:88-95. doi:10.1016/j.lungcan.2017.07.003
[28] Chudecka-Głaz AM, Cymbaluk-Płoska AA, Menkiszak JL, Sompolska-Rzechuła AM, Tołoczko-Grabarek AI, Rzepka-Górska IA. Serum HE4, CA125, YKL-40, bcl-2, cathepsin-L and prediction optimal debulking surgery, response to chemotherapy in ovarian cancer. Journal of ovarian research. 2014;7:62. doi:10.1186/1757-2215-7-62
[29] Aarenstrup Karlsen M, Høgdall C, Nedergaard L, Philipsen Prahm K, Schou Karlsen NM, Weng Ekmann-Gade A, et al. HE4 as a predictor of adjuvant chemotherapy resistance and survival in patients with epithelial ovarian cancer. APMIS. 2016;124(12):1038-45. doi:10.1111/apm.12625
[30] Madeira K, Dondossola ER, Farias BFDE, Simon CS, Alexandre MCM, Silva BR, et al. Mesothelin as a biomarker for ovarian carcinoma: a meta-analysis. An Acad Bras Cienc. 2016;88(2):923-32. doi:10.1590/0001-3765201620150107
[31] Hanaoka T, Hasegawa K, Kato T, Sato S, Kurosaki A, Miyara A, et al. Correlation Between Tumor Mesothelin Expression and Serum Mesothelin in Patients with Epithelial Ovarian Carcinoma: A Potential Noninvasive Biomarker for Mesothelin-targeted Therapy. Mol Diagn Ther. 2017;21(2):187-98. doi:10.1007/s40291-017-0255-2
[32] Wang H, Zhu L, Gao J, Hu Z, Lin B. Promotive role of recombinant HE4 protein in proliferation and carboplatin resistance in ovarian cancer cells. Oncol Rep. 2015;33(1):403-12. doi:10.3892/or.2014.3549